High expression of DOCK2 indicates good prognosis in acute myeloid leukemia

Hu, Ning; Pang, Yifan; Zhao, Hongmian; Si, Chaozeng; Ding, Hui; Chen, Li; Wang, Chao; Qin, Tong; Li, Qianyu; Han, Yu; Dai, Yifeng; Zhang, Yijie; Shi, Jinlong; Wu, Depei; Zhang, Xinyou; Cheng, Zhiheng; Fu, Lin

doi:10.7150/jca.33244



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2019; 10(24):6088-6094. doi:10.7150/jca.33244 This issue Cite

Research Paper

High expression of DOCK2 indicates good prognosis in acute myeloid leukemia

Ning Hu¹, Yifan Pang², Hongmian Zhao¹, Chaozeng Si³, Hui Ding¹, Li Chen¹, Chao Wang¹, Tong Qin¹, Qianyu Li¹, Yu Han¹, Yifeng Dai⁴, Yijie Zhang⁵, Jinlong Shi⁶, Depei Wu⁷, Xinyou Zhang^8✉, Zhiheng Cheng^4✉, Lin Fu^1,9,10✉

1. Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, 475000, China
2. Department of Medicine, William Beaumont Hospital, Royal Oak, MI 48073, USA
3. Department of Operations and Information Management, China-Japan Friendship Hospital, Beijing, 100029, China
4. Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
5. Department of Respiratory, Huaihe Hospital of Henan University, Kaifeng, 475000, China
6. Department of Biomedical Engineering, Chinese PLA General Hospital, Beijing, 100853, China
7. Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China
8. Department of Hematology, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen 518020, China
9. Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China
10. Translational Medicine Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China

✉ Corresponding authors: Lin Fu, MD. PhD. Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, 475000, China. Email: fulin022com, Tel: +86-0371-23906543, Fax: +86-0371-23906543. Zhiheng Cheng. Department of Pathology and Medica More

Citation:

Hu N, Pang Y, Zhao H, Si C, Ding H, Chen L, Wang C, Qin T, Li Q, Han Y, Dai Y, Zhang Y, Shi J, Wu D, Zhang X, Cheng Z, Fu L. High expression of DOCK2 indicates good prognosis in acute myeloid leukemia. J Cancer 2019; 10(24):6088-6094. doi:10.7150/jca.33244. https://www.jcancer.org/v10p6088.htm

Other styles

Abstract

DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse prognostic effect in acute myeloid leukemia (AML). We first analyzed data of 85 AML patients who were treated with chemotherapy and had available DOCK1 to DOCK11 expression information and found that DOCK1 and DOCK2 had prognostic significance in AML. In view of the known prognosis of DOCK1 in AML, we then explored the prognostic role of DOCK2. One hundred fifty-six AML patients with DOCK2 expression data were extracted from The Cancer Genome Atlas (TCGA) database and enrolled in this study. Patients were divided based on treatment modality into the chemotherapy group and the allogeneic hematopoietic stem cell transplant (allo-HSCT) group. Each group was divided into two groups by the median expression levels of DOCK2. In the chemotherapy group, high DOCK2 expression was associated with longer event-free survival (EFS, P=0.001) and overall survival (OS, P=0.007). In the allo-HSCT group, EFS and OS were not significantly different between high and low DOCK2 expression groups. Multivariate analysis showed that high DOCK2 expression was an independent favorable prognostic factor for both EFS and OS in all patients (all P<0.05). In conclusion, our results indicated that high DOCK2 expression, in contrast to DOCK1, conferred good prognosis in AML.

Keywords: acute myeloid leukemia, DOCK2, allogeneic hematopoietic stem cell transplantation, chemotherapy, prognosis

Citation styles

APA

Hu, N., Pang, Y., Zhao, H., Si, C., Ding, H., Chen, L., Wang, C., Qin, T., Li, Q., Han, Y., Dai, Y., Zhang, Y., Shi, J., Wu, D., Zhang, X., Cheng, Z., Fu, L. (2019). High expression of DOCK2 indicates good prognosis in acute myeloid leukemia. Journal of Cancer, 10(24), 6088-6094. https://doi.org/10.7150/jca.33244.

ACS

Hu, N.; Pang, Y.; Zhao, H.; Si, C.; Ding, H.; Chen, L.; Wang, C.; Qin, T.; Li, Q.; Han, Y.; Dai, Y.; Zhang, Y.; Shi, J.; Wu, D.; Zhang, X.; Cheng, Z.; Fu, L. High expression of DOCK2 indicates good prognosis in acute myeloid leukemia. J. Cancer 2019, 10 (24), 6088-6094. DOI: 10.7150/jca.33244.

NLM

CSE

Hu N, Pang Y, Zhao H, Si C, Ding H, Chen L, Wang C, Qin T, Li Q, Han Y, Dai Y, Zhang Y, Shi J, Wu D, Zhang X, Cheng Z, Fu L. 2019. High expression of DOCK2 indicates good prognosis in acute myeloid leukemia. J Cancer. 10(24):6088-6094.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.